SCHEMBL10323741

SCHEMBL10323741

CSc1nccc(-c2n[nH]c3nc(Cl)ncc23)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CCNA2 P20248 3/20 0.37
CDK2 P24941 3/20 0.37
CDK5 Q00535 3/20 0.37
CDK5R1 Q15078 3/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
CCNA1 P78396 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
CSNK1E P49674 2/20 0.36
GABRA1 P14867 1/20 0.36
MAPK14 Q16539 4/20 0.34
CSNK1D P48730 2/20 0.34
DYRK1A Q13627 2/20 0.34
JAK3 P52333 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10323041 0.78 EIF2AK2 (0.40) CCNA2CDK2CDK5CDK5R1CCNT1
SCHEMBL10322584 0.76 MKNK1 (0.42) CCNA2CDK2CDK5CDK5R1CCNT1
SCHEMBL10324888 0.73 MKNK1 (0.41) CCNA2CDK2CCNA1MAPK14DYRK1A
SCHEMBL10322994 0.73 RPS6KA5 (0.35) GABRA1MAPK14TGFBR1RPS6KA5DYRK1B
SCHEMBL5096658 0.73 LRRK2 (0.55) LMNAL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL31084688 0.73 LRRK2 (0.55) LMNAL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL10323534 0.73 MKNK1 (0.43) CCNA2CDK2CCNA1MAPK14DYRK1A
SCHEMBL11338542 0.72 DYRK1A (0.39) DYRK1AJAK3DYRK1B
SCHEMBL10322500 0.71 MKNK1 (0.50) LMNAPOLBL3MBTL1HPGDMAPK14
SCHEMBL4998135 0.70 ALDH1A1 (0.46) LMNAKDM4EALDH1A1HPGDMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 US disclosed
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 US disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 US disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184508-A1 PYRAZOLO PYRIMIDINES TYMS, TYMP, TP53 LMNA 1710/4885POLB 230/4885TDP1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.